Antimicrobial Resistance of Mycobacterium Tuberculosis A Global Health Challenge

Antimicrobial resistance (AMR) in Mycobacterium tuberculosis (M. tuberculosis) has emerged as one of the most pressing challenges in global public health. The development of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of tuberculosis (TB) has rendered conventional treatment regimens less effective, leading to increased morbidity, mortality, and treatment costs. This paper explores the mechanisms behind antimicrobial resistance in M. tuberculosis, the contributing factors such as improper treatment adherence and diagnostic delays, and global strategies for managing resistant TB. Furthermore, it discusses current diagnostic tools, therapeutic advancements, and the importance of surveillance and policy frameworks in mitigating the spread of resistant TB strains. The increasing incidence of drug resistance has made it necessary to reassess traditional TB control programs and adapt new evidence-based approaches. The implementation of rapid diagnostics, patient-centered treatment plans, community education, and international collaboration has become pivotal in achieving long-term control and eventual elimination of drug-resistant TB. Through detailed case studies and review of current literature, this research underscores the urgency of addressing antimicrobial resistance in TB through a multidisciplinary and globally coordinated effort. Keywords: Mycobacterium tuberculosis, antimicrobial resistance, MDR-TB, XDR-TB, global health, tuberculosis treatment, drug susceptibility, public health, TB diagnosis, WHO strategies